Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tenaya Therapeutics Inc

0.6706
-0.0054-0.80%
Post-market: 0.67950.0089+1.33%19:59 EDT
Volume:1.59M
Turnover:1.06M
Market Cap:109.08M
PE:-0.58
High:0.6900
Open:0.6900
Low:0.6441
Close:0.6760
Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Tenaya Therapeutics (TNYA), ImmunoPrecise Antibodies (IPA)

TIPRANKS
·
31 Jul

Tenaya Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
31 Jul

Promising Developments in Tenaya Therapeutics’ Clinical Trials Earn Buy Rating from Analyst

TIPRANKS
·
30 Jul

Positive Safety Reviews and Promising Interim Data Bolster Buy Rating for Tenaya Therapeutics

TIPRANKS
·
30 Jul

Tenaya Therapeutics Inc: Plans to Report Longer-Term Follow-up Data From Cohort 1 and Initial Data From Cohort 2 in Q4 of This Year

THOMSON REUTERS
·
30 Jul

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

GlobeNewswire
·
30 Jul

Tenaya Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
31 May

Tenaya Therapeutics' SVP Finance Tomohiro Higa Reports Disposal of Common Shares

Reuters
·
17 May

Tingley Whittemore, Chief Medical Officer, Reports Disposal of Tenaya Therapeutics Inc. Common Shares

Reuters
·
17 May

CEO Ali Faraz Reports Disposal of Tenaya Therapeutics Inc. Common Shares

Reuters
·
17 May

Analysts’ Top Healthcare Picks: Tenaya Therapeutics (TNYA), Green Thumb Industries (GTBIF)

TIPRANKS
·
12 May

Strong Buy Recommendation for Tenaya Therapeutics Amid Promising Trial Results and Financial Stability

TIPRANKS
·
10 May

Tenaya Therapeutics Reports Q1 2025 Financial Results

TIPRANKS
·
08 May

Buy Rating for Tenaya Therapeutics Driven by Promising Clinical Developments and Strategic Restructuring

TIPRANKS
·
08 May

BRIEF-Tenaya Therapeutics Q1 Net Income USD -26.864 Million

Reuters
·
08 May

Tenaya Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Apr

Tenaya announces interim data from ongoing RIDGE study

TIPRANKS
·
25 Apr

Promising Clinical Trial Results for TN-201 Support Buy Rating for Tenaya Therapeutics

TIPRANKS
·
31 Mar

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

GlobeNewswire
·
31 Mar

BRIEF-Tenaya Therapeutics Inc - On Mar 27, Co Approves Restructuring Plan - SEC Filing

Reuters
·
29 Mar